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1. RESUMEN 
 
La tuberculosis es una de las enfermedades más prevalentes a nivel mundial. Es 
ocasionada por un complejo bacteriano conocido como complejo Mycobacterium 
tuberculosis (MTBC). A pesar de ser una enfermedad curable, con el desarrollo y 
dispersión de cepas resistentes a drogas se ha limitado la alterativa terapéutica. 
La identificación rápida y correcta de la resistencia a través del análisis de 
mutaciones puntuales implicadas en la resistencia a anti-tuberculosis es 
fundamental para prevenir el desarrollo y dispersión de cepas multirresistentes. 
Nuestro objetivo es caracterizar las mutaciones más frecuentes en genes 
relacionados con la resistencia a anti-tuberculosis y determinar el genotipo de 
MTBC que circula en nuestra región, apartando información para el control y 
prevención del desarrollo de cepas de MTBC resistentes a drogas. Métodos: Se 
analizaron 82 aislados de MTBC colectados de un hospital de tercer nivel en 
Quito-Ecuador. Se secuenció las regiones determinantes de la resistencia en los 
genes rpoB, katG, gyrA y rrs y las regiones promotoras inhA y eis. La 
identificación de sublinajes se realizó utilizando Repeticiones en Tándem de 
Número Variable de Unidades Repetitivas Intercaladas Micobacterianas (MIRU-
VNTR). Resultados: Se registraron  48 aislados MDR, 14 aislados INH-
monoresistentes, 5 aislados RIF-monoresistentes y 15 aislados sensibles a todas 
las drogas analizadas. 48 aislamientos RIF-resistentes muestran al menos una 
mutación en rpoB. La mutación Ser531Leu fue el más prevalente. 47 aislamientos 
resistentes a INH  tenían una mutación en el gen katG y/o en el promotor inhA; la 
substitución Ser315Asn y [C (-15) T]  fueron las mutaciones más prevalentes en 
katG y promotor inhA, respectivamente. Tres mutaciones encontradas en este 
estudio no se han registrado en la base de datos TB Drug Resistance Mutation: 
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Met515Ile en rpoB [GenBank: KP732541]; Thr314Ala [GenBank: KP732540] y 
Thr324Ser en katG [GenBank: KP732539]. El análisis MIRU-VNTR reveló la 
presencia de LAM (17,1%), Ghana (15,9%), Haarlem (8,5%), tipo S (4,9%), 
Camerún (3,7%) y Beijing (1,2%). Conclusiones: Las mutaciones de resistencia 
más frecuentes fueron consistentes con los reportados para la región. 
Encontramos tres nuevas mutaciones no reportados en los genes rpoB y katG, 
que podrían estar relacionados con la resistencia a RIF e INH. Registramos el 
primer informe del genotipo Beijing en Ecuador. 
 
Palabras clave: Mycobacterium tuberculosis, resistencia, mutaciones, sub-linajes.  
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2. ABSTRACT 
 
Background: Tuberculosis is one of the world’s deadliest bacterial infectious 
diseases. Mycobacterium tuberculosis complex (MTBC) genotypes have been 
related to acquire more virulent determinants and have an innate predisposition for 
developing multi-resistance. Rapid and correct identification of the antimicrobial 
susceptibility and analyses of punctual mutations involved in antimicrobial 
resistance are critical to prevent the development and dissemination of new MTBC 
multi-resistant strains. Due to the lack of information about the lineages of MTBC 
circulating in Ecuador and the drug resistance molecular genes associated to 
them, we aim to determine the most common resistance related mutations and 
genotypes present in our region, contributing with information for control and 
prevention of new MTBC multi-resistant strains. Methods: We analysed 82 MTBC 
isolates in an 11 year period from a tertiary hospital in Quito, Ecuador. Resistance 
determining regions of rpoB, katG, gyrA and rrs genes, and promoter regions of 
inhA and eis, were sequenced. Identification and clustering of sub-lineages was 
done using mycobacterial interspersed repetitive-unit-variable-number tandem-
repeat (MIRU-VNTR) analysis. Results: We registered 48 MDR, 14 INH-
monoresistant, 5 RIF-monoresistant and 15 susceptible isolates. 48 RIF-resistant 
isolates showed at least one mutation in rpoB. Mutation Ser531Leu was the most 
prevalent. 47 INH-resistant isolates (47/62) had a mutation in the katG gene 
and/or inhA promoter; the substitution Ser315Asn and [C(-15)T] (13/62) were the 
most prevalent mutations in katG and inhA promoter, respectively. Three 
mutations found in this study have not been registered in the TB Drug Resistance 
Mutation database: Met515Ile in rpoB [GenBank:KP732541]; Thr314Ala 
[GenBank:KP732540] and Thr324Ser in katG [GenBank:KP732539]. The MIRU-
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VNTR analysis revealed the presence of LAM (17.1%), Ghana (15.9%), Haarlem 
(8.5%), S-type (4.9%), Cameroon (3.7%), and Beijing (1.2 %). Conclusions: The 
most frequent resistance mutations were consistent with those reported in the 
region. We found three new unreported mutations in rpoB and katG genes, which 
could be related to rifampicin and isoniazid resistance. We registered the first 
report of Beijing genotype in Ecuador. The sequencing of genes’ hot-spot regions 
involved in resistance used in this study can be a rapid method to determine new 
mutations associated with clinically important resistance in MTBC.  
 
Key Words: Mycobacterium tuberculosis, resistance, mutations, sub-lineages 
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Introduction  
Tuberculosis (TB) continues to be one of the main causes of morbidity and 
mortality burden worldwide. It’s estimated that 2 billion people have a latent 
infection [1]. Nine million new cases of TB and 1.5 million deaths were reported in 
2013. A great percentage of these cases were registered in poor or developing 
countries [1, 2]. 
TB is spread from person to person through the air for the disease mainly 
affects the lungs [3]. The pathogenic agent of TB is a bacteria from the 
Mycobacterium tuberculosis complex (MTBC). This complex includes two human 
pathogens, M. tuberculosis (main etiological agent of TB in humans) and M. 
africanum. It also includes M. bovis a clade of mycobacteria that can infect 
humans but manly infects animals [3].  
Despite being a curable disease, with the emergence and spread of drug 
resistant MTBC strains, mainly multi drug-resistant (MDR) and extremely drug-
resistant (XDR), TB possess a challenge for therapeutic alternatives compromising 
the success of disease control programs [1, 4]. The World Health Organization 
(WHO) reported around 480 000 new cases of MDR tuberculosis in 2013 [1], 10% 
of these XDR [5]. Moreover, in 2011 in India was reported first case of Totally 
drug-resistant TB (TDR) [1]. 
MDR is defined as rifampicin (RIF) and isoniazid (INH) resistant isolates, 
the first line most effective anti-tuberculosis drugs. XDR isolates are resistant to 
RIF, INH, fluoroquinolone (FLQ) and at least one of the injectable agents: 
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amikacin (AMK), kanamycin (KAN) or capreomycin (CAP) [2, 5]. TDR is defined as 
resistant to all available first-line and second-line TB drugs [2].  
Resistance in TB originates by accumulation of specific mutations in genes 
which encode antibiotic target sites [6]. About 95% of RIF-resistant clinical MTBC 
isolates have mutations in the RIF resistance-determining region (RRDR); an 81-
bp region in the rpoB gene that encodes RNA polymerase, the RIF target [5, 6, 7, 
8]. 
Mutations in katG gene and inhA promotor are mainly involved in INH-
resistance [6]. Nearly 50% of INH-resistant MTBC isolates have mutations in katG 
gene, which encodes the catalase-peroxidase KatG enzyme that activates INH [9]. 
Another 25% of INH-resistant isolates have mutations in inhA promoter that is 
associated with the over expression of enoyl-acyl carrier InhA. InhA is involved in 
the synthesis of micolitic acid, the main target of the active INH [5].  
The FLQ-resistance in MTBC is mainly caused by mutations in conserved 
regions called quinolone resistance-determining regions (QRDRs) in the gyrA and 
gyrB genes. These genes code for DNA-gyrase subunits and the mutations inhibit 
DNA supercoiling and DNA replication. The mutations in QRDR of gyrA are mainly 
involved in FLQ-resistance [10, 11]. 
The injectable second-line drugs inhibit protein synthesis in bacteria by 
binding to the 30S subunit of the ribosomal 16S rRNA. The mutations in the rrs 
gene producing KAN, AMK and CAP resistance are mainly found at nucleotide 
positions 1401, 1402 and 1484. A mutation at positions 1401 or 1484 is associated 
with high resistance to all injectable agents, while mutations at position 1402 
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confer high resistance to CAP and resistance to KAN in a lower level. Mutations in 
eis promoter gene cause overexpression of aminoglycoside-acetyl transferase, 
generating low level KAN resistance [6, 12]. 
Epistatic interactions between mutations conferring drug resistance and 
compensatory mutations that increase the fitness of the strains also play an 
important role in the emergence of MDR-TB and XDR-TB [13]. In addition, several 
studies have shown that certain strains of MTBC, from different lineages, are more 
prone to develop drug resistance, due to their specific genetic background [14]. Of 
the six lineages of MTBC (1, Indo-Oceanic; 2, East-Asian; 3, East-African-Indian; 
4, Euro-American; 5, West I and 6, West Africa II), the East-Asian lineage is most 
commonly associated with multi-drug resistance, including Beijing family strains [3, 
14, 15]. 
In order to understand the dynamics of TB transmission, regional 
knowledge of MTBC diversity, population structure and main MTBC lineages is 
needed.  
In Ecuador, the prevalence of pulmonary TB is approximately 60 cases per 
100 000 inhabitants, 26% of all cases treated and 4.9% of all new cases were 
identified as MDR [1]. Unfortunately, there are no studies regarding genetic 
mutations in clinical isolates of MTBC in Ecuador, reported in indexed literature. 
Several studies have shown the distribution of lineages and sub-lineages in Latin 
America, confirming the Euro-American lineage as predominant in the region [17]. 
However, to our knowledge, no studies have been conducted in order to determine 
predominant lineages and sub-lineages in Ecuador. 
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In this study, we determined the most common mutations associated with 
drug resistance in MTBC isolates and identified the diversity of lineages and sub-
lineages present in the population. Mycobacterial Interspersed Repetitive-Unit–
Variable-Number Tandem-Repeat (MIRU-VNTR) analysis offers the solution to 
this issue as a discriminative and powerful genotyping tool [16]. 
Methods 
Bacteria Strains  
To study the antimicrobial resistance in MTBC we selected eighty two 
clinical isolates of MTBC; forty eight phenotypically resistant to RIF and INH, 
fourteen resistant to INH and five resistant to RIF. Additionally, we randomly 
selected fifteen susceptible isolates. MTBC clinical isolates were donated by the 
Departamento de Microbiología y Tuberculosis del Hospital Vozandes, Quito. The 
isolates were cultivated in the Lowenstein-Jensen solid medium (35° C, 5% CO2). 
The species identification was confirmed by sequencing the rrs rRNA gene. 
PCR amplification and sequencing  
Genomic DNA was extracted using the commercial kit High Pure PCR 
template preparation kit (Roche, Switzerland), following the manufacture’s 
specifications.  
To characterize the drug resistant related mutations, we analyzed the genes 
rpoB, katG, gyrA and rrs, and the promoter region of inhA and eis. PCR 
amplifications were achieved with primers listed in Table 1.  
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The PCR protocol was followed as described elsewhere with modifications 
[7, 18, 19, 20]. Briefly, the reactions were prepared in a final volume of 25 µl, 
including 12.5 µl of GoTaq Green Master Mix (Promega, USA), 10 µM of each 
primer (Invitrogen, USA) and 5 µl of genomic DNA. 
 
PCR products were resolved in 2% agarose gels. The amplification 
products were purified using the Wizard® SV Gel and PCR Clean-Up System 
(Promega, USA), following manufacture’s specifications. Sequencing was 
performed at Macrogen, South Korea. The sequences were aligned and analyzed 
in Geneious Pro 5.6.4 software. The strain H37Rv was used as a control in all the 
analysis. 
Determination of the main M. tuberculosis lineages 
MIRU-VNTR genotyping was achieved through PCR amplification of 15 loci, 
following the procedure described by Supply et al. [16]. PCR products were sized 
on 2% agarose gels using the Image Lab 4.0.1 Rev G (BioRad, USA). The allelic 
profile of each locus was calculated using the corresponding conversion table [16]. 
To determine the MTB strain lineages, MIRU-VNTR 15-loci profiles were analyzed 
in the open access database MIRU-VNTRplus (http://www.miru-vntrplus.org). The 
genotypic profile was used to construct an UPGMA tree. 
Statistical analyses  
The statistical analysis was implemented using the IBM® SPSS® Statistics 
software 22.0. Categorical data analysis was achieved applying X2 test. The 
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Hunter-Gaston index (HGDI) of MIRU-VNTR types was calculated as described 
previously [21]. A cluster was defined as two or more isolates sharing the same 
MIRU-VNTR genotypic profile. The clustering rate was defined as (nc–C)/N, where 
nc is the total number of clustered cases, C is the number of clusters, and N is the 
total number of cases in the sample [22]. A P value < 0.05 was considered to be 
statistically significant. 
 
Results  
Bacteria strains 
A total of eighty two Mycobacterium tuberculosis isolates, collected from 
2002 to 2013, were tested. Of these, sixty seven were drug resistant: including 
forty eight (58.5%) MDR isolates, fourteen (17.1%) INH-monoresistant isolates 
and five (6.1%) RIF-monoresistant isolates. The remaining fifteen isolates (18.3%) 
exhibited susceptibility to all drugs (Table 3). 
Drug resistance associated with genetic mutations in MTBC 
Mutations associated with resistance to RIF were located mostly in the 81-
bp hot-spot region of the rpoB gene. Fifty-three RIF-resistant isolates (53/82) were 
analyzed, of which forty-eight (90.6%) had at least one mutation in this gene, 
whereas five (9.4%) resistant isolates lacked these mutations (P = 0).  
Eight types of missense mutations were identified in rpoB. These mutations 
involved codons 511, 516, 526 and 531. The most prevalent mutation was the 
substitution Ser531Leu (31/53; 58.5%); followed by the transitions His526Asp 
12 
 
 
(5/53; 9.4%); Asp516Val (4/53; 7.5%) and His526Leu (3/53; 5.7%). The remaining 
mutations were reported less frequently: the change His526Tyr was observed in 
two isolates (3.8%), whereas the variations His526Leu (1.9%) and Leu511Arg 
(1.9%) were found in one isolate. Finally one (1.9%) isolate showed a double 
mutation: the changes Met515Ile and Asp516Tyr (P< 0.00001). We found one 
mutation that is not described in the TB Drug Resistance Mutation data base 
(https://tbdreamdb.ki.se/Info/); codon 515 [GenBank:KP732541] (Table 4). 
 Among the 29 RIF-sensitive isolates, seven had a mutation at rpoB gene, 
five isolates (17.2%) were reported with the change Ser531Leu, one (3.4%) isolate 
with a change the His526Arg and one ( 3.4%) isolate with transition His526Tyr (P< 
0.00001). (Table 3). 
To determine the genotypic resistance to INH, katG gene and inhA 
promoters were sequenced. Sixty-two INH-resistant isolates were analyzed, of 
which forty-seven (75.8%) had a mutation in the katG gene and/or inhA promoter. 
Of the forty-seven isolates, two (3.3%) had a mutation in both loci; while thirty-four 
(54.8%) presented mutations only in katG, and eleven (17.7%) showed mutations 
only in ihnA promoter. Fifteen (24.2%) of the sixty-two INH-resistant isolates 
lacked the mutation in both loci (P = 0.000195). 
We found seven mutations in the katG, five of which are known to correlate 
with INH resistance. We found two mutations not previously reported in the TB 
Drug Resistance Mutation database,Thr314Ala (1.6%) [GenBank:KP732540] and 
Thr324Ser (1.6%) [GenBank:KP732539]. Also, the genotypic profile of one if the 
isolates could not be established (1.6%). 
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The most prevalent change in katG was the replacement Ser315Asn 
(31/62; 50.0%). The mutation Ser315Thr was found in two isolates (3.2%) (P< 
0.00001). The twenty INH-susceptible isolates did not show mutations in katG. 
Of the sixty two INH-resistant isolates thirteen (21.0%) presented a 
mutation at inhA promoter. In the study population, only the change [C (-15) T] 
was found 15 nucleotides upstream of the start codon. Six (6/20; 30.0%) of the 
twenty INH-susceptible isolates had a mutation [C (-15) T] in the inhA promoter (P 
= 0.405145). 
Furthermore, in the study we analyzed the loci mainly involved with second 
line tuberculosis drug resistance. FQ genotypic resistance was determined 
analyzing the RDRQ sequence of the gyrA gene, while, resistance to 
aminoglycosides (AMK, KAN, CAP) was determined by the analysis of rrs gene 
and eis promoter (Table 5).  
Of the eighty-two isolates studied, six (7.3%) presented a point mutation in 
the gyrA, these mutations were registered in codons 90, 91 and 94. The most 
common mutation was the change Asp94Try (2/82; 2.4%), followed the changes 
Asp94Gly (1/82; 1.2%), Asp94Asn (1/82; 1.2%), Ala90Val (1/82; 1.2%) and 
Ser91Pro (1/82; 1.2%).  
Only four (4.9%) isolates of the eighty two tested showed a change of 
nucleotide adenine to guanine in position 1401 of the rrs. No mutations in eis 
promoter were registered. 
In total, we identified sequence changes in eight INH-monoresistant 
isolates, eleven RIF-monoresistant isolates, thirty eight MDR isolates, three pre-
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XDR isolates and three XDR isolates. Eighteen isolates showed no mutation in the 
analyzed loci, and the genotypic profile of one isolate could not be determined. 
MIRU-VNTR genotype profiles of the MTBC isolates 
The eighty-two isolates were genotyped with MIRU-VNTR using a 15 loci 
panel. Six different genotypes were determined: Cameroon, Ghana, Haarlem, 
LAM (Latin American Mediterranean), S-type and Beijing. Forty (48.8%) genotypes 
could not be identified in the database; these strains were classified as orphan 
types. The most prevalent genotype was LAM (14; 17.1%), followed by Ghana (13; 
15.9%), Haarlem (7; 8.5%), S-type (4/82; 4.9%), Cameroon (3; 3.7%), and Beijing 
(1/82; 1.2 %).  
The UPGMA tree, based on the MIRU-VNTR 15-loci, showed a total of 73 
different patterns, which included six clusters, one with five isolates and the 
remaining clusters with two isolates each (Fig 1). In total, fifteen strains grouped 
into clusters and sixty seven strains with unique pattern were reported (11% 
clustering rate). Genotyping showed a high diversity in the study population; the 
Hunter & Gaston discriminatory index (HDGI) results in a value of 0.995.  
The minimum spanning tree analysis indicated that the eighty-two isolates 
were divided into ten clonal complexes (CC1-CC10) and thirty-six singletons. The 
CC3, CC7, CC8, CC9 and CC10 were conformed of strains of the LAM sub-
lineage; the CC1 had mostly strains of the Ghana sub-lineage, the CC5 was 
conformed of strains of Haarlem sub-lineage, strains of sub-lineages Cameroon 
belonged to CC6 and the orphans strains belonged to CC2 and CC4. Also, the 
Beijing sub-lineage strain is one of the thirty-six singletons (Fig 2). 
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Genotyping and mutational analysis 
We were unable to correlate a particular mutation with a specific sub-
lineage as the mutations found were distributed randomly in the study population 
and were not associated with a sub-lineage in this study 
Discussion 
Early detection of resistance in MTBC is important to achieve a successful 
TB treatment. Conventional methods to detect resistance to most anti-TB drugs 
are very laborious and time consuming [8] compared to molecular diagnosis. 
However, molecular analysis has limitations because it requires complete 
information about the type and frequency of resistant related mutations linked to 
the region [23], also most of the commercial systems available have a narrow 
panel of mutations which is not specific for any region 
Recent studies have shown that 10.0-40.0% of mutations causing 
resistance in clinical isolates have not been identified, so it is important to find new 
mutations that could lead to the emergence of resistance in MTBC [24]. Three 
mutations found in this study have not been previously reported in the TB Drug 
Resistance Mutation database (https://tbdreamdb.ki.se/Info/). The new mutations 
Met515Ile in rpoB; Thr314Ala in katG and Thr324Ser in katG, were only identified 
in drug resistant isolates, however, more studies are necessary to confirm their 
role in resistance. 
Studies have shown that mutations in the RDRR of rpoB region are found in 
95.0% of RIF-resistant isolates [18, 25]. In our study, a significant correlation 
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between phenotypic and genotypic profile of resistance was observed, 90.6% (P = 
0.00). 
Mutations at codons 531, 526 and 516 were recorded in forty-seven of the 
fifty-three resistant isolates. The change Ser531Leu was the most frequent (P = 
0.00032) as reported in other studies [8, 26, 27]. However, the frequency (of the 
mutations His526Asp and the Asp516Val differ with the values reported for other 
geographic regions [28].  
Similar to other studies [8, 27], we found that 9.4% of RIF-resistant isolates 
did not show mutations in RDRR. Furthermore, seven of the twenty-two RIF-
sensitive isolates were cataloged as resistant to RIF by sequencing of the rpoB 
gene. . This is because not all of the rpoB gene genotypic changes affect the 
phenotypic resistance to RIF, the position and nature of the mutation (amino acid 
substitution) is strongly correlated with the MIC of RIF resistance [28]. It is known 
that mutations at codons 516, 518, 522, 529 and 533 give low resistance to RIF 
[26]. Several studies have shown that conventional diagnostic methods, mainly 
broth cultures based, where the average range of MIC for the critical concentration 
of resistance is at least 4 mg/mL, may categorize some isolates as sensitive RIF, 
although these present a mutation in the rpoB gene [29, 30, 31]. 
It is known that the katG, inhA, ahpC, ndh and oxyR genes are involved 
with resistance to INH. However, many studies found that resistance to INH in 
TBMC is mainly correlated to mutations in the katG gene and the inhA promoter 
[8, 26]. We also found a strong correlation (P = 0.000195) between INH resistance 
and mutations in katG and/or the inhA promoter; 75.8% of INH-resistant isolates 
presented a mutation in these loci.  
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Our sample had a high prevalence (53.2%) of mutations at codon 315 of 
katG. Other studies, have reported this mutation in up to 95% of INH-resistant 
isolates, which is why this region is considered a molecular target for resistance to 
INH [8, 14, 26, 32]. 
Among the registered mutations at katG codon 315, Ser315Asn was 
reported as the most frequent (P <0.00001), unlike what has been found in other 
studies, where the change Ser315Thr has significant clinical importance [18]. This 
contrast shows that the frequency and the type of mutation in katG can vary with 
the geographical regions [8, 24, 29]. No INH-sensitive isolates had mutations in 
katG. We only found the change [C (-15) T] in the inhA promoter. In this study 21% 
of INH-resistant isolates showed this mutation, indicating that INH resistance is 
largely associated with a katG. Six of the twenty INH-sensitive isolates showed 
mutation in the inhA promoter, this is possibly because mutations in the inhA 
promoter are associated with a low level of INH-resistance [8]. 
Finally, fifteen (24.2%) INH-resistant isolates showed no mutation in the two 
analyzed loci. This discrepancy may be attributed to the presence of mutations 
outside the analyzed region or other genes involved in INH-resistance [8]. 
FQ are the base treatment for MDR-TB [33]. gyrA and gyrB genes have 
mainly been associated with FQ resistance. It has been shown that mutations in 
gyrB, are less common than mutations in gyrA [34In this study only the QRDR of 
gyrA gene was analyzed. It was observed that 7.3% of the analyzed isolates had a 
mutation in this region, so they can be categorized as FQ resistant. Mutations in 
gyrA were found only in MDR isolates. In our study, the change Asp94Tyr was the 
most prevalent, however, other studies have reported changes of Asp94Gly as the 
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most common [26, 10]. The finding of FQ genotypically resistant isolates suggests 
the need of implementing FQ in the susceptibility tests for MDR isolates. 
The second-line injectable agents (AMK, KAN and CAP) are used in the 
treatment of MDR-TB [35]. Although AMK and KAN are aminoglycoside antibiotics 
and CAP is a macrocyclic peptide, cross resistance between these anti-TB has 
been described widely [26, 29]. Mutations in the rrs gene encoding for 16sRNA are 
mainly involved to a high level of resistance to these antibiotics [35, 36]. However, 
recent studies have reported that low levels of resistance to these agents, mainly 
KAN, are due to the presence of mutations in eis promoter, related to 
overexpression of aminoglycoside acetyltransferase [37]. Because of its 
relationship with resistance to second-line injectable agents the rrs gene and the 
eis promoter were analyzed in this study. 4.9% of the studied isolates had a 
mutation associated with resistance to second-line injectable agents. The change 
of adenine for thymine in the 1401 position of the gene was reported. This is 
consistent with previous descriptions, where 30 to 90% of the isolates resistant to 
this anti-TB present this change [37]. No changes were registered in the eis 
promoter. These mutations were found in MDR isolates, indicating that it is 
important to test susceptibility to second line drugs in all MDR isolates to provide 
appropriate treatment. 
The typing method MIRU-VNTR allows epidemiologist to investigate the 
dynamics of TB transmission, to find possible focal infection and, to identify 
outbreaks. This typing method can be also used for phylogenetic characterization 
of TB infections, allowing us to know the lineage / sub lineage and clonal 
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complexes of a MTBC population [23, 38, 39]. Using MIRU-VNTR 15-loci 
technique, it was possible to classify within a lineage to 51.2%.  
We observed a great deal of genetic diversity in the population. Six different 
genotypes were found, with the LAM sub-lineage being the most predominant 
(17.1%), followed by Ghana (15.9%), Haarlem (8.5%), S-type (4.9%), Cameroon 
(3.7%) and Beijing (1/82; 1.2 %). Our results are similar to previous reports from 
Colombia and Peru, where LAM or Haarlem are the predominant sub-lineages [17, 
40]. 
The sub-lineages Ghana, LAM, Haarlem, Cameroon, and S-type belong to 
the Euro-American (lineage 4), one of the six lineages mainly reported in Europe, 
America and Middle East [17, 41]. 
One isolate was classified in the Beijing sub-lineage, belonging to the East-
Asian (lineage 2). While seven countries in South America, including Colombia 
and Peru, have reported the Beijing genotype [42], this is the first report of this 
sub-lineage in Ecuador. Identifying the Beijing genotype is important due to their 
ability to acquire resistance to drugs, their hyper mutability, transmission capacity 
and virulence [43]. 
Grouping rate is a marker used to determine the recent transmission of 
TBM [39]. In this study the presence of six clusters is recorded. However, 
clustering index was 11%, indicating that the isolates do not have an 
epidemiological link. 
UPGMA dendrogram analysis showed that each isolate from a cluster had a 
different mutational profile (Figure 1).This is consistent with that described by 
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Wang et al. (2014) suggesting that the resistance in MTBC isolates is not 
conserved among the defined strains of a cluster but individual isolates of each 
cluster evolve unique characteristics during TB treatment [23].  
No significant association between the lineage / sub lineage and mutational 
profile was found but it has been shown that each strain generic background plays 
a major role in the development of drug resistance, meaning a single mutation in 
different lineage isolates also present a different resistance levels [14].      
Even though, the sample size was limited, our results establish a basic 
understanding of the molecular epidemiology of MBTC in Ecuador. Additionally, 
we show that the sequencing of hot-spot genetic regions is a useful in screening 
for MBTC. However, to determine new mutations related to resistance it is likely 
necessary to sequence the complete open reading frame of each gene [29]. It’s 
important to note that for a better correlation between the genotypic patterns and 
phenotypic susceptibility profiles, the Minimum Inhibitory Concentration (MIC) of 
the isolates to anti-TB drugs is required, unfortunately in our countries the MIC in 
TB techniques are yet to be established. Finally, despite the high discrimination 
obtained with 15 MIRU-VNTR panel, in order to create better grouping analysis we 
proposed the 24 MIRU-VNTR panel [22]. 
Conclusion 
The accurate and rapid detection of MTBC resistant isolates is critical for 
proper treatment of TB. Molecular detection of resistance by analyzing mutations 
in related genes is an excellent choice for proper treatment of this disease. We 
found a high correlation between genotypic and phenotypic resistance in our 
21 
 
 
Ecuadorian samples, demonstrating the reliability of this detection method. Our 
results suggest a high utility of the identification of mutations in rpoB and katG to 
infer resistance to RIF and INH. 
Furthermore, although the frequency of some mutations associated with 
resistance is similar to what reported in other countries (Ser531Leu in rpoB), 
others mutations frequencies are unique (Ser315Asn in katG), suggesting that the 
type and frequency of each mutation varies depending on geographic region.   
This highlighting the importance of having good data local populations 
rather than relying on data from populations in distinct region. 
Three new mutations were found, one in the rpoB and two in the katG, 
which could be involved with RIF and INH resistance respectively; demonstrating 
the need to look for mutations not yet identified as potential causes of resistance. 
Regarding the genomic diversity of MTBC, the most predominant sub-lineage in 
this study was LAM, similar to those reported in neighboring countries. 
Furthermore, Beijing genotype was recorded for the first time in Ecuador. These 
results provide invaluable information for supplementing the epidemiological map 
of MTBC for the region, and contribute to the understanding of the TB resistance 
dynamics in Ecuador. 
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Figure 1. UPGMA dendrogram based on the 15-loci MIRU-VNTR data for 
eighty-two clinical isolates of MTBC. Six different genotypes were determined, 
labeled with different color. The MIRU-VNTR genotypic profile is included. A total 
of 73 different patterns were found, which included six clusters with a maximum of 
five and minimum two isolates; clustering rate was 11,0%. The phenotypic 
resistance to RIF and INH is observed, as well as the mutations present in rpoB, 
katG, inhA promoter, gyrA, rrs and eis promoter.  
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Figure 2. Minimum spanning tree based on MIRU-VNTR 15-loci profiles. Each 
circle represents a different strain, the frequency (number of strains) is determined 
by the color of each circle (white: 1 isolate, purple: 2 isolates and blue: 5 isolates) 
Each CC is marked by a different color. 
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Table 1. Primers used in resistance identification 
 
Gene Sequences (5′-3′) 
size 
(bp) 
Annealing 
temperatur
e 
Resistanc
ea 
Referenc
e  
rpoB 
rpoB-F: AGGACGTGGAGGCGATCA 
245 58 °C RIF 7, 18 
rpoB-R: GGTTTCGATCGGGCACAT 
katG 
katG-F: TGGCCGCGGCGGTCGACATT 
420 62 °C INH 7, 18 
katG-R: GGTCAGTGGCCAGCATCGTC 
inhA 
promoter 
inhA-P-F: CCTCGCTGCCCAGAAAGGGA 
249 60 °C INH 7, 18 
inhA-P-R: ATCCCCCGGTTTCCTCCGGT 
gyrA 
gyrA-F: CAGCTACATCGACTATGCGA 
320 55 °C FQ 19 
gyrA-R: GGCTTCGGTGTACCTCAT 
rrs 
27F: AGAGTTTGATCMTGGCTCAG 
1200 72 °C 
AMK, KAN, 
CAP 
20 
1492R:TACGGYTACCTTGTTACGACTT 
eis 
promoter 
Eis-P-F: AATTCGTCGCTGATTCTCGC 
210 55 °C 
AMK, KAN, 
CAP 
20 
Eis-P-R: TGAAATCGGTGAAACTGGCC 
 
a
 RIF, rifampicin; INH, isoniazid; FQ,  fluoroquinolone; AMK, amikacin; KAN, kanamycin; CAP, 
Capreomycin. 
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Table 2. Locus and primers used for amplification of MURU-VNTR 
 
Locus Alias 
Repeat unit length 
(bp) 
PCR primers pair (5´-3´) 
580 MIRU 4 77 
MIRU 4F  GCGCGAGAGCCCGAACTGC 
MIRU 4 R GCGCAGCAGAAACGCCAGC 
2996 MIRU 26 51 
MIRU 26F TAGGTCTACCGTCGAAATCTGTGAC 
MIRU 26R CATAGGCGACCAGGCGAATAG 
802 MIRU 40 54 
MIRU 40 F GGGTTGCTGGATGACAACGTGT 
MIRU 40 R GGGTGATCTCGGCGAAATCAGATA 
960 MIRU 10 53 
MIRU 10F GTTCTTGACCAACTGCAGTCGTCC 
MIRU 10R GCCACCTTGGTGATCAGCTACCT 
1644 MIRU 16 53 
MIRU 16F TCGGTGATCGGGTCCAGTCCAAGTA 
MIRU16R CCCGTCGTGCAGCCCTGGTAC 
3192 MIRU 31 53 
MIRU 31F ACTGATTGGCTTCATACGGCTTTA 
MIRU 31R GTGCCGACGTGGTCTTGAT 
424 Mtub04 51 
Mtub04F CTTGGCCGGCATCAAGCGCATTATT 
Mtub04R GGCAGCAGAGCCCGGGATTCTTC 
577 ETR C 58 
ETR C F CGAGAGTGGCAGTGGCGGTTATCT 
ETR C R AATGACTTGAACGCGCAAATTGTGA 
2165 ETRA 75 
ETR A F AAATCGGTCCCATCACCTTCTTAT 
ETR A R CGAAGCCTGGGGTGCCCGCGATTT 
2401 Mtub30 58 
Mtub30 F CTTGAAGCCCCGGTCTCATCTGT 
Mtub30 R ACTTGAACCCCCACGCCCATTAGTA 
3690 Mtub39 58 
Mtub39 F CGGTGGAGGCGATGAACGTCTTC 
Mtub39 R TAGAGCGGCACGGGGGAAAGCTTAG 
4156 
QUB-
4156 
59 
QUB-4156 F TGACCACGGATTGCTCTAGT 
QUB-4156 R GCCGGCGTCCATGTT 
2163b QUB-11b 69 
QUB-11b F CGTAAGGGGGATGCGGGAAATAGG 
QUB-11b R CGAAGTGAATGGTGGCAT 
1955 Mtub21 57 
Mtub21 F AGATCCCAGTTGTCGTCGTC 
Mtub21 R CAACATCGCCTGGTTCTGTA 
4052 QUB-26 111 
QUB-26 F AACGCTCAGCTGTCGGAT 
QUB-26 R CGGCCGTGCCGGCCAGGTCCTTCCCGAT 
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Table 3. Resistance profiles of MTBC isolates collected between 2002 -2013 
 
Profile N° of isolates % of isolates 
Sensitive 15 18.3 
INH 14 17.1 
RIF 5 6.1 
INH+RIF 48 58.5 
Total 82 100.0 
 
INH, Isoniazid; RIF, Rifampicin
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Table 4 Mutations identified in drug resistance-associated loci in MTBC 
 
 
 Gene Codon 
Base 
mutation 
Amino 
acid 
change
g
 
Drug
a
 
N° of genotypic 
resistant 
isolates/ N° of 
phenotypic 
resistant 
isolates 
N° of 
genotypic 
resistant 
isolates/ N° of 
phenotypic 
susceptible 
isolates 
P value 
rpoB None None None RIF 5/53 22/29 0.00121 
rpoB 511 CTG→CCG Leu→Arg RIF 1/53 0/29 0.45671 
rpoB 516 GAC→GTC Asp→Val RIF 4/53 0/29 0.12929 
rpoB 516/515
d
 
GAC→TAC Asp→Tyr 
RIF 1/53 0/29 0.45671 
ATG→ATC
f
 Met→Ile
b
 
rpoB 526 CAC → CTC His→Leu RIF 3/53 0/29 0.19178 
rpoB 526 CAC→CGC His→Arg RIF 1/53 1/29 0.66120 
rpoB 526 CAC→GAC His→Asp RIF 5/53 0/29 0.11874 
rpoB 526 CAC→TAC His→Tyr RIF 2/53 1/29 0.94020 
rpoB 531 TCG→TTG Ser→Leu RIF 31/53 5/29 0.00032 
katG None None None INH 26/62 0/20 0.00045 
katG 314 ACC→GCC
b
 Thr→Ser INH 1/62 0/20 0.56769 
katG 315 AGC→ACA Ser→Thr INH 2/62 0/20 0.41610 
katG 315 AGC→ACC Ser→Asn INH 31/62 0/20 >0.00001 
katG 324 AAC→TCC
b
 Thr→Ser INH 1/62 0/20 0.56769 
katG ND
e
 ND ND INH 1/62 1/20 0.39318 
inhA 
promoter 
None None None INH 49/62 14/20 >0.00001 
inhA 
promoter 
 C(-15)T  INH 13/62 6/20 0.405145 
 
a 
RIF, Rifampicin; INH, Isoniazid  
b 
Mutations not previously reported. 
c 
None, no mutation  
d 
Multiple mutations in one isolate. 
e 
Not determined 
f
 A, adenine; G, guanine; C, cytosine; T, thymine 
g 
His, Histidine; Asp, Aspartate; Val, Valine; Leo, Leucine; Tyr, Tyrosine; Arg, Arginine; Met, 
Methionine; Ile, Isoleucine; Ser, Serine; Ala, Alanine, Thr, Threonine, Asn, Asparagine; Gly, 
Glycine; Pro, Proline.  
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Table 5 Mutations associated second line drug resistance 
 
Gene Codon Base mutation 
Amino acid 
change 
Drug
a
 
N°  (%) of 
isolates 
gyrA 94 GAC→GGC Asp→Gln FQ 1 (1.2%) 
gyrA 94 GAC→TAC Asp→Try FQ 2 (2.4%) 
gyrA 94 GAC→AAC Asp→Asn FQ 1 (1.2%) 
gyrA 90 GCG→CTG Ala→Val FQ 1 (1.2%) 
gyrA 91 TCG→CCG Ser→Pro FQ 1 (1.2%) 
gyrA None None None FQ 77 (92.8%) 
rrs None 1401A→T None AMK, KAN,CAP 4 (4.9%) 
rrs None None None AMK, KAN,CAP 78 (95.1%) 
eis promoter None None None AMK, KAN,CAP 82 (100.0%) 
 
a FLQ, fluoroquinolone; AMK,  amikacin; KAN, kanamycin; CAP capreomycin, A, adenine; G, 
guanine; C, cytosine; T, thymine; Asp, Aspartate; Gln, Glutamine, Val, Valine; Tyr, Tyrosine; Ser, 
Serine; Asn, Asparagine; Pro, Proline. 
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Instructions for authors 
 
 
The title page should: 
 provide the title of the article 
 list the full names, institutional addresses and email addresses for all authors 
 indicate the corresponding author 
Please note: 
 the title should include the study design, for example "A versus B in the 
treatment of C: a randomized controlled trial X is a risk factor for Y: a case 
control study" 
 abbreviations within the title should be avoided 
 
Abstract 
The Abstract of the manuscript should not exceed 350 words and must be 
structured into separate sections: Background, the context and purpose of the 
study; Methods, how the study was performed and statistical tests used; Results, 
the main findings; Conclusions, brief summary and potential implications. Please 
minimize the use of abbreviations and do not cite references in the abstract. Trial 
registration, if your research reports the results of a controlled health care 
intervention, please lists your trial registry, along with the unique identifying 
number (e.g. Trial registration: Current Controlled Trials ISRCTN73824458). 
Please note that there should be no space between the letters and numbers of 
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your trial registration number. We recommend manuscripts that report randomized 
controlled trials follow the CONSORT extension for abstracts. 
Additional non-English language abstract 
An additional non-English language abstract can be included within the article. The 
additional abstract should be placed after the official English language abstract in 
the submitted manuscript file and should not exceed 350 words. Please ensure 
you indicate the language of your abstract. In addition to English, we can support 
German, Spanish, French, Norwegian and Portuguese abstracts. 
Keywords 
Three to ten keywords representing the main content of the article. 
Background 
The Background section should be written in a way that is accessible to 
researchers without specialist knowledge in that area and must clearly state - and, 
if helpful, illustrate - the background to the research and its aims. Reports of 
clinical research should, where appropriate, include a summary of a search of the 
literature to indicate why this study was necessary and what it aimed to contribute 
to the field. The section should end with a brief statement of what is being reported 
in the article. 
Methods 
The methods section should include the design of the study, the setting, the type 
of participants or materials involved, a clear description of all interventions and 
comparisons, and the type of analysis used, including a power calculation if 
appropriate. Generic drug names should generally be used. When proprietary 
brands are used in research, include the brand names in parentheses in the 
Methods section. 
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For studies involving human participants a statement detailing ethical approval and 
consent should be included in the methods section. For further details of the 
journal's editorial policies and ethical guidelines see 'About this journal'. 
For further details of the journal's data-release policy, see the policy section in 
'About this journal'. 
Results and discussion 
The Results and discussion may be combined into a single section or presented 
separately. Results of statistical analysis should include, where appropriate, 
relative and absolute risks or risk reductions, and confidence intervals. The 
Results and discussion sections may also be broken into subsections with short, 
informative headings. 
Conclusions 
This should state clearly the main conclusions of the research and give a clear 
explanation of their importance and relevance. Summary illustrations may be 
included. 
Availability of supporting data 
Annals of Clinical Microbiology and Antimicrobials encourages authors to deposit 
the data set(s) supporting the results reported in submitted manuscripts in a 
publicly-accessible data repository, when it is not possible to publish them as 
additional files. This section should only be included when supporting data are 
available and must include the name of the repository and the permanent identifier 
or accession number and persistent hyperlink(s) for the data set(s). The following 
format is required: 
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"The data set(s) supporting the results of this article is (are) available in the 
[repository name] repository, [unique persistent identifier and hyperlink to 
dataset(s) in http:// format]." 
Where all supporting data are included in the article or additional files the following 
format is required: 
"The data set(s) supporting the results of this article is (are) included within the 
article (and its additional file(s))" 
We also recommend that the data set(s) be cited, where appropriate in the 
manuscript, and included in the reference list. 
A list of available scientific research data repositories can be found here. A list of 
all BioMed Central journals that require or encourage this section to be included in 
research articles can be found here. 
List of abbreviations 
If abbreviations are used in the text they should be defined in the text at first use, 
and a list of abbreviations can be provided, which should precede the competing 
interests and authors' contributions. 
Competing interests 
A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with other 
people or organizations. Authors must disclose any financial competing interests; 
they should also reveal any non-financial competing interests that may cause them 
embarrassment were they to become public after the publication of the 
manuscript. 
Authors are required to complete a declaration of competing interests. All 
competing interests that are declared will be listed at the end of published articles. 
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Where an author gives no competing interests, the listing will read 'The author(s) 
declare that they have no competing interests'. 
When completing your declaration, please consider the following questions: 
Financial competing interests 
In the past three years have you received reimbursements, fees, funding, or salary 
from an organization that may in any way gain or lose financially from the 
publication of this manuscript, either now or in the future? Is such an organization 
financing this manuscript (including the article-processing charge)? If so, please 
specify. 
Do you hold any stocks or shares in an organization that may in any way gain or 
lose financially from the publication of this manuscript, either now or in the future? 
If so, please specify. 
Do you hold or are you currently applying for any patents relating to the content of 
the manuscript? Have you received reimbursements, fees, funding, or salary from 
an organization that holds or has applied for patents relating to the content of the 
manuscript? If so, please specify. 
Do you have any other financial competing interests? If so, please specify. 
Non-financial competing interests 
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation 
to this manuscript? If so, please specify. 
If you are unsure as to whether you, or one your co-authors, has a competing 
interest please discuss it with the editorial office. 
Authors' contributions 
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In order to give appropriate credit to each author of a paper, the individual 
contributions of authors to the manuscript should be specified in this section. 
According to ICMJE guidelines, An  'author' is generally considered to be someone 
who has made substantive intellectual contributions to a published study. To 
qualify as an author one should 1) have made substantial contributions to 
conception and design, or acquisition of data, or analysis and interpretation of 
data; 2) have been involved in drafting the manuscript or revising it critically for 
important intellectual content; 3) have given final approval of the version to be 
published; and 4) agree to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the 
content. Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship. 
We suggest the following kind of format (please use initials to refer to each 
author's contribution): AB carried out the molecular genetic studies, participated in 
the sequence alignment and drafted the manuscript. JY carried out the 
immunoassays. MT participated in the sequence alignment. ES participated in the 
design of the study and performed the statistical analysis. FG conceived of the 
study, and participated in its design and coordination and helped to draft the 
manuscript. All authors read and approved the final manuscript. 
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged 
include a person who provided purely technical help, writing assistance, or a 
department chair who provided only general support. 
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Authors' information 
You may choose to use this section to include any relevant information about the 
author(s) that may aid the reader's interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors' 
qualifications, current positions they hold at institutions or societies, or any other 
relevant background information. Please refer to authors using their initials. Note 
this section should not be used to describe any competing interests. 
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authorship. Please also include the source(s) of funding for each author, and for 
the manuscript preparation. Authors must describe the role of the funding body, if 
any, in design, in the collection, analysis, and interpretation of data; in the writing 
of the manuscript; and in the decision to submit the manuscript for publication. 
Please also acknowledge anyone who contributed materials essential for the 
study. If a language editor has made significant revision of the manuscript, we 
recommend that you acknowledge the editor by name, where possible. 
The role of a scientific (medical) writer must be included in the acknowledgements 
section, including their source(s) of funding. We suggest wording such as 'We 
thank Jane Doe who provided medical writing services on behalf of XYZ 
Pharmaceuticals Ltd.' 
Authors should obtain permission to acknowledge from all those mentioned in the 
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Endnotes 
Endnotes should be designated within the text using a superscript lowercase letter 
and all notes (along with their corresponding letter) should be included in the 
Endnotes section. Please format this section in a paragraph rather than a list. 
References 
All references, including URLs, must be numbered consecutively, in square 
brackets, in the order in which they are cited in the text, followed by any in tables 
or legends. Each reference must have an individual reference number. Please 
avoid excessive referencing. If automatic numbering systems are used, the 
reference numbers must be finalized and the bibliography must be fully formatted 
before submission. 
Only articles, clinical trial registration records and abstracts that have been 
published or are in press, or are available through public e-print/preprint servers, 
may be cited; unpublished abstracts, unpublished data and personal 
communications should not be included in the reference list, but may be included 
in the text and referred to as "unpublished observations" or "personal 
communications" giving the names of the involved researchers. Obtaining 
permission to quote personal communications and unpublished data from the cited 
colleagues is the responsibility of the author. Footnotes are not allowed, but 
endnotes are permitted. Citations in the reference list should include all named 
authors, up to the first six before adding 'et al.' 
Any in press articles cited within the references and necessary for the reviewers' 
assessment of the manuscript should be made available if requested by the 
editorial office. 
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Preparing illustrations and figures  
Illustrations should be provided as separate files, not embedded in the text file. 
Each figure should include a single illustration and should fit on a single page in 
portrait format. If a figure consists of separate parts, it is important that a single 
composite illustration file be submitted which contains all parts of the figure. There 
is no charge for the use of color figures. 
Please read our figure preparation guidelines for detailed instructions on 
maximising the quality of your figures. 
Formats 
The following file formats can be accepted: 
 PDF (preferred format for diagrams) 
 DOCX/DOC (single page only) 
 PPTX/PPT (single slide only) 
 EPS 
 PNG (preferred format for photos or images) 
 TIFF 
 JPEG 
 BMP 
Figure legends 
The legends should be included in the main manuscript text file at the end of the 
document, rather than being a part of the figure file. For each figure, the following 
information should be provided: Figure number (in sequence, using Arabic 
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numerals - i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); 
detailed legend, up to 300 words. 
Please note that it is the responsibility of the author(s) to obtain permission from 
the copyright holder to reproduce figures or tables that have previously been 
published elsewhere. 
 
Preparing tables  
Each table should be numbered and cited in sequence using Arabic numerals (i.e. 
Table 1, 2, 3 etc.). Tables should also have a title (above the table) that 
summarizes the whole table; it should be no longer than 15 words. Detailed 
legends may then follow, but they should be concise. Tables should always be 
cited in text in consecutive numerical order. 
Smaller tables considered to be integral to the manuscript can be pasted into the 
end of the document text file, in A4 portrait or landscape format. These will be 
typeset and displayed in the final published form of the article. Such tables should 
be formatted using the 'Table object' in a word processing program to ensure that 
columns of data are kept aligned when the file is sent electronically for review; this 
will not always be the case if columns are generated by simply using tabs to 
separate text. Columns and rows of data should be made visibly distinct by 
ensuring that the borders of each cell display as black lines. Commas should not 
be used to indicate numerical values. Color and shading may not be used; parts of 
the table can be highlighted using symbols or bold text, the meaning of which 
should be explained in a table legend. Tables should not be embedded as figures 
or spreadsheet files. 
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Larger datasets or tables too wide for a landscape page can be uploaded 
separately as additional files. Additional files will not be displayed in the final, laid-
out PDF of the article, but a link will be provided to the files as supplied by the 
author. 
Tabular data provided as additional files can be uploaded as an Excel spreadsheet 
(.xls ) or comma separated values (.csv). As with all files, please use the standard 
file extensions. 
Preparing additional files  
Although Annals of Clinical Microbiology and Antimicrobials does not restrict the 
length and quantity of data included in an article, we encourage authors to provide 
datasets, tables, movies, or other information as additional files. 
Please note: All Additional files will be published along with the article. Do not 
include files such as patient consent forms, certificates of language editing, or 
revised versions of the main manuscript document with tracked changes. Such 
files should be sent by email to acma@biomedcentral.com, quoting the Manuscript 
ID number. 
Results that would otherwise be indicated as "data not shown" can and should be 
included as additional files. Since many weblinks and URLs rapidly become 
broken, Annals of Clinical Microbiology and Antimicrobials requires that supporting 
data are included as additional files, or deposited in a recognized repository. 
Please do not link to data on a personal/departmental website. The maximum file 
size for additional files is 20 MB each, and files will be virus-scanned on 
submission. 
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Additional files can be in any format, and will be downloadable from the final 
published article as supplied by the author. We recommend CSV rather than PDF 
for tabular data. 
Certain supported files formats are recognized and can be displayed to the user in 
the browser. These include most movie formats (for users with the Quicktime 
plugin), mini-websites prepared according to our guidelines, chemical structure 
files (MOL, PDB), geographic data files (KML). 
If additional material is provided, please list the following information in a separate 
section of the manuscript text: 
 File name (e.g. Additional file 1) 
 File format including the correct file extension for example .pdf, .xls, .txt, .pptx 
(including name and a URL of an appropriate viewer if format is unusual) 
 Title of data 
 Description of data 
Additional files should be named "Additional file 1" and so on and should be 
referenced explicitly by file name within the body of the article, e.g. 'An additional 
movie file shows this in more detail [see Additional file 1]'. 
Additional file formats 
Ideally, file formats for additional files should not be platform-specific, and should 
be viewable using free or widely available tools. The following are examples of 
suitable formats. 
 Additional documentation 
PDF (Adode Acrobat) 
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 Animations 
SWF (Shockwave Flash) 
 Movies 
MP4 (MPEG 4) 
MOV (Quicktime) 
 Tabular data 
XLS, XLSX (Excel Spreadsheet) 
CSV (Comma separated values) 
As with figure files, files should be given the standard file extensions. 
Mini-websites 
Small self-contained websites can be submitted as additional files, in such a way 
that they will be browsable from within the full text HTML version of the article. In 
order to do this, please follow these instructions: 
1. Create a folder containing a starting file called index.html (or index.htm) in 
the root. 
2. Put all files necessary for viewing the mini-website within the folder, or sub-
folders. 
3. Ensure that all links are relative (ie "images/picture.jpg" rather than 
"/images/picture.jpg" or "http://yourdomain.net/images/picture.jpg" or 
"C:\Documents and Settings\username\My Documents\mini-
website\images\picture.jpg") and no link is longer than 255 characters. 
4. Access the index.html file and browse around the mini-website, to ensure 
that the most commonly used browsers (Internet Explorer and Firefox) are 
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able to view all parts of the mini-website without problems, it is ideal to 
check this on a different machine. 
5. Compress the folder into a ZIP, check the file size is under 20 MB, ensure 
that index.html is in the root of the ZIP, and that the file has .zip extension, 
then submit as an additional file with your article. 
Style and lenguage 
General 
Currently, Annals of Clinical Microbiology and Antimicrobials can only accept 
manuscripts written in English. Spelling should be US English or British English, 
but not a mixture. 
There is no explicit limit on the length of articles submitted, but authors are 
encouraged to be concise. 
Annals of Clinical Microbiology and Antimicrobials will not edit submitted 
manuscripts for style or language; reviewers may advise rejection of a manuscript 
if it is compromised by grammatical errors. Authors are advised to write clearly and 
simply, and to have their article checked by colleagues before submission. In-
house copyediting will be minimal. Non-native speakers of English may choose to 
make use of a copyediting service. 
Help and advice on scientific writing 
The abstract is one of the most important parts of a manuscript. For guidance, 
please visit our page on Writing titles and abstracts for scientific articles. 
Tim Albert has produced for BioMed Central a list of tips for writing a scientific 
manuscript. American Scientist also provides a list of resources for science writing. 
For more detailed guidance on preparing a manuscript and writing in English, 
please visit the BioMed Central author academy.  
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Anexo 1. Perfil fenotípico y genotípico de susceptibilidad a anti-TB en aislados clínicos de Mycobacterium tuberculosis  
# 
Ais-
lado 
Fecha de 
aislamiento 
Susceptibi
lidad a 
anti-TB 
Mutaciones relacionadas con la resistencia a anti-TB de primera y segunda línea 
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1 3 18-1-02 S S A A C →T (-15) A A A 
2 9 13-12-03 S S A A C →T (-15) A A A 
3 44 16-5-02 S S A A A A A A 
4 53 20-6-02 R S 531TCG→TTG A C →T (-15) 94 GAC→GGC 1401 A→G A 
5 55 22-7-02 S S A A A A A A 
6 58 22-4-02 R R 526 CAC→TAC 315 AGC→ACC A A A A 
7 63 9-5-02 S R 531TCG→TTG A C →T (-15) A A A 
8 80 22-7-02 S S A A A A A A 
9 98 5-8-02 S R 531TCG→TTG 315 AGC→ACC A A A A 
10 140 20-11-02 R R 531TCG→TTG 315 AGC→ACC A A A A 
11 150 3-1-03 R R 531TCG→TTG 315 AGC→ACC A A A A 
12 151 9-9-03 R R A A A A A A 
13 159 30-1-00 R R 526 CAC→GAC A A A A A 
14 166 6-3-03 S S A A A A A A 
15 174 6-3-03 S R A A A A A A 
16 180 5-5-03 R R 531TCG→TTG 315 AGC→ACC A A A A 
17 181 6-5-03 S S A A A A A A 
18 185 28-5-03 S R A A A A A A 
19 204 25-7-03 R R 531TCG→TTG 315 AGC→ACC A A A A 
20 208 23-8-03 R R 531TCG→TTG 315 AGC→ACC A A A A 
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Anexo 1. Perfil fenotípico y genotípico de susceptibilidad a anti-TB en aislados clínicos de Mycobacterium tuberculosis 
(Continuación) 
# 
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21 214  R R 526 CAC→GAC 315 AGC→ACC A A A A 
22 221 27-7-03 S R A A C →T (-15) A A A 
23 225 12-8-03 R R 516 GAC→GTC 315 AGC→ACC A A A A 
24 238 16-9-03 S R A A A A A A 
25 239 17-9-03 S R A ND A A A A 
26 244 30-9-03 R R 526 CAC→CGC A A A A A 
27 246 5-9-03 S R A 315 AGC→ACC A A A A 
28 247 19-9-03 S R A A A A A A 
29 258 14-10-03 S S A A A A A A 
30 276 19-12-03 S R A 315 AGC→ACC A A A A 
31 287 20-1-04 R R 531 TCG→TTG 324 ACC→TCC A A A A 
32 303 10-2-04 R R 526 CAC→GAC 315 AGC→ACC A A A A 
33 309 2-3-04 R R 531 TCG→TTG 315 AGC→ACA A A A A 
34 315 3-3-04 S R A 315 AGC→ACC A A A A 
35 369 4-8-04 S S 531 TCG→TTG A C →T (-15) A A A 
36 389 30-8-09 R R 
516 GAC→TAC 
515 ATG→ATC 
315 AGC→ACC A A A A 
37 395 6-10-04 R R 526 CAC→ CTC A A A A A 
38 398 21-10-04 S S A A A A A A 
39 405 17-9-04 R R 531 TCG→TTG 315 AGC→ACC A A A A 
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Anexo 1. Perfil fenotípico y genotípico de susceptibilidad a anti-TB en aislados clínicos de Mycobacterium tuberculosis 
(Continuación) 
# 
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40 406 16-9-04 S R 526 CAC→TAC 315 AGC→ACC A A A A 
41 419 24-12-04 R R A A C →T (-15) A A A 
42 421 12-1-05 R R 531 TCG→TTG A A A A A 
43 445 28-3-05 R R 526 CAC→TAC 315 AGC→ACC A A A A 
44 447 16-4-05 R R 531 TCG→TTG A A A A A 
45 459 27-4-05 R R A A A A A A 
46 467 26-5-05 S R 526 CAC→CGC 315 AGC→ACC A A A A 
47 478 5-8-05 R R 531 TCG→TTG 315 AGC→ACC A A A A 
48 479 18-6-05 S S A A A A A A 
49 485 30-6-05 R R 531 TCG→TTG A C →T (-15) A A A 
50 492 13-7-05 R S A A A A A A 
51 535 26-9-05 S R A A A A A A 
52 538 10-1-05 R R 531 TCG→TTG A C →T (-15) 94 GAC→TAC 1401 A → G A 
53 547 25-10-05 R S 531 TCG→TTG A A A A A 
54 550 23-11-05 R R 531 TCG→TTG 315 AGC→ACC A A A A 
55 559 24-1-06 S S A A A A A A 
56 570 12-7-05 R R 
526 CAC → 
GAC 
315 AGC→ACC A 90 GCG→CTG A A 
57 572 20-1-06 R R 
526 CAC → 
GAC 
A C →T (-15) A A A 
58 608 21-5-06 R R 531 TCG→TTG A A A A A 
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Anexo 1. Perfil fenotípico y genotípico de susceptibilidad a anti-TB en aislados clínicos de Mycobacterium tuberculosis 
(Continuación) 
 
# 
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59 612 25-5-06 R R 531 TCG→TTG A C →T (-15) 94 GAC→TAC 1401 A → G A 
60 617 6-9-06 R R 531 TCG→TTG 314 ACC→GCC C →T (-15) A A A 
61 623 27-9-06 R R 531 TCG→TTG A A A A A 
62 625 14-9-06 R R 531 TCG→TTG 315 AGC→ACC A A A A 
63 630 15-9-06 R R 531 TCG→TTG 315 AGC→ACC A A A A 
64 634 12-10-06 R S 531 TCG→TTG A C →T (-15) A A A 
65 648 18-10-06 R R 516 GAC→GTC A A A A A 
66 658 23-1-07 R R 511 CTG→CCG 315 AGC→ACC A A A A 
67 666 13-2-07 R R 526 CAC→ CTC 315 AGC→ACC A 91 TCG → CCG A A 
68 668 14-2-07 R R A 315 AGC→ACC A A A A 
69 682 3-5-07 S S 531 TCG→TTG A A A A A 
70 686 23-10-09 R R 531 TCG→TTG A C →T (-15) A A A 
71 691 15-6-07 S S A A A A A A 
72 697 7-8-07 R R 531 TCG→TTG 315 AGC→ACC A 94 GAC → AAC A A 
73 706 5-10-07 S S 531 TCG→TTG A A A A A 
74 760 8-9-08 R S 516 GAC→GTC A C →T (-15) A A A 
75 765 9-10-08 R R 531 TCG→TTG 315 AGC→ACA A A A A 
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Anexo 1. Perfil fenotípico y genotípico de susceptibilidad a anti-TB en aislados clínicos de Mycobacterium tuberculosis 
(Continuación) 
# 
Ais-
lado 
Fecha de 
aislamiento 
Susceptibili
dad a anti-
TB 
Mutaciones relacionadas con la resistencia a anti-TB de primera y segunda línea 
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76 766 17-11-08 R R 531 TCG→TTG 315 AGC→ACC A A A A 
77 770 16-11-09 R R 531 TCG→TTG 315 AGC→ACC A A A A 
78 844 23-10-09 R R 531 TCG→TTG A C →T (-15) A A A 
79 849 24-2-10 R R 531 TCG→TTG A C →T (-15) A A A 
80 899 30-11-10 R R 516 GAC→GTC A C →T (-15) A A A 
81 932 9-12-11 R R 526 GAC→CTC 315→ACC A A A A 
82 977 14-1-13 R R 531 TCG→TTG 315→ACC C →T (-15) A 1401 A→G A 
78 844 23-10-09 R R 531 TCG→TTG A C →T (-15) A A A 
79 849 24-2-10 R R 531 TCG→TTG A C →T (-15) A A A 
80 899 30-11-10 R R 516 GAC→GTC A C →T (-15) A A A 
81 932 9-12-11 R R 526 GAC→CTC 315→ACC A A A A 
 
RIF, Rifampicina; INH, Isoniacida; R, resistente; S, sensible; anti-TB, anti-tuberculosis; A, ausente, ND, no determinado  
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Anexo 2. Perfil MIRU-VNTR 15-Loci en aislados clínicos de Mycobacterium tuberculosis 
# 
Aislado 
MIRU-VNTR 15 loci 
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1 3 2 4 2 4 3 3 3 4 2 1 2 2 2 3 7 LAM 
2 9 2 5 4 2 4 3 2 4 2 2 4 2 5 2;0 6 ND 
3 44 2 6 2 2 3 3 5 3 2 4 3 1 4 5; 3 7 ND 
4 53 2 4 2 4 3 3 3 3 3 4 3 3 6 4 6 Ghana 
5 55 2 5 3 4 3 3 2 3 3 4 3 4 4 3 7 Haarlem 
6 58 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
7 63 2 3 1 1 3 3 5 4 2 2 1 2 4 3 6 ND 
8 80 3 5 1 3 3 3 4 4 2 1 2 2 4 3 7 ND 
9 98 1 4 2 4 2 3 2 3 3 4 3 3 7 4 6 ND 
10 140 2 4 2 4 2 3 2 3 3 4 3 3 7 4 6 ND 
11 150 1 4 2 4 3 3 2 3 3 4 3 3 7 5 6 ND 
12 151 2 5 2 3 3 3 2 4 2 2 3 2 4 3 8 Cameroon 
13 159 2 8 5 4 3 2 3 4 3 1 2 2 2 3 6 LAM 
14 166 2 5 4 5 3 3 2 3 3 4 3 4 4 3 7 Haarlem 
15 174 2 3 5 4 3 3 4 4 2 2 1 2 4 3 7 ND 
16 180 4 3 1 2 3 3 4 4 3 2 1 2 7 1 4 ND 
17 181 2 6 2 3 3 3 4 3 2 4 3 1 4 3 7 ND 
18 185 2 4 3 3 3 3 3 4 2 1 3 3 2 4 7 ND 
19 204 2 5 0 3 3 2 3 4 2 1 3 2 2 3 6 LAM 
20 208 2 5 0 4 3 2 3 4 2 1 3 2 2 3 6 LAM 
21 214 1 4 2 3 3 3 4 3 3 4 2 3 7 4 6 ND 
22 221 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
23 225 2 1 0 4 3 3 3 4 2 1 1 2 2 1 6 ND 
24 238 2 5 3 5 3 3 1 3 3 4 4 3 4 2 6 Haarlem 
25 239 2 5 2 4 4 3 3 3 3 4 3 3 7 4 6 ND 
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Anexo 2. Perfil MIRU-VNTR 15-Loci en aislados clínicos de Mycobacterium tuberculosis (Continuación) 
# 
Aislado 
MIRU-VNTR 15 loci 
Linaje 
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26 244 2 5 2 3 5 2 2 3 2 2 3 2 4 2 5 ND 
27 246 2 5 4 3 3 3 2 4 4 2 3 2 3 3 2 Cameroon 
28 247 2 5 3 5 3 3 2 3 2 4 3 3 5 2 7 Haarlem 
29 258 2 8 4 4 3 2 3 4 2 1 2 2 2 3 6 LAM 
30 276 2 5 2 3 3 3 2 4 2 2 3 2 3 2 8 ND 
31 287 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
32 303 1 4 2 4 4 4 2 3 3 4 3 3 7 4 6 ND 
33 309 2 5 1 4 3 4 4 4 2 1 2 2 4 3 8 ND 
34 315 2 6 3 3 3 3 4 3 2 4 3 1 4 4 4 ND 
35 369 2 5 3 5 3 4 2 3 3 4 3 3 5 2 4 Haarlem 
36 389 1 4 2 4 3 3 2 3 3 4 3 3 7 5 6 ND 
37 395 2 4 2 4 3 3 2 3 3 4 3 3 7 5 6 ND 
38 398 2 5 4 4 3 3 4 4 2 2 1 3 3 3 4 LAM 
39 405 1 4 2 4 3 4 2 3 3 4 3 4 7 4 6 ND 
40 406 2 5 0 3 2 3 4 4 2 1 2 2 4 3 6 LAM 
41 419 2 5 3 4 3 3 1 3 3 4 3 2 5 2 7 Haarlem 
42 421 3 5 2 3 2 2 2 4 4 2 3 1 4 1 9 ND 
43 445 2 5 1 4 2 3 4 4 2 1 2 2 4 3 6 LAM 
44 447 2 5 6 4 3 2 3 4 4 1 2 0 2 3 7 LAM 
45 459 3 4 4 3 3 3 3 4 4 2 3 1 3 1 8 S 
46 467 2 5 5 2 3 3 3 4 2 1 2 2 2 3 6 LAM 
47 478 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
48 479 2 5 5 3 2 3 3 4 3 2 3 2 4 2 5 ND 
49 485 2 3 1 2 3 3 4 4 2 2 1 1 4 3 6 ND 
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Anexo 2. Perfil MIRU-VNTR 15-Loci en aislados clínicos de Mycobacterium tuberculosis (Continuación) 
# 
Aislado 
MIRU-VNTR 15 loci 
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50 492 3 5 4 3 2 3 1 3 4 2 3 2 3 1 10 S 
51 535 3 4 4 3 2 3 2 4 4 2 3 1 4 1 8 S 
52 538 2 4 1 4 3 3 2 3 3 4 3 3 6 4 6 Ghana 
53 547 2 5 2 3 4 3 2 4 2 2 3 0 4 2 6 ND 
54 550 2 5 0 4 4 3 4 4 2 1 2 2 2 3 6 ND 
55 559 3 5 4 3 3 3 3 4 4 2 3 2 3 1 10 S 
56 570 1 4 2 4 3 3 2 3 3 4 3 2 7 4 6 ND 
57 572 2 5 6 3 4 2 2 4 2 2 3 1 4 2 5 ND 
58 608 2 5 2 4 2 2 3 4 2 1 2 2 2 3 7 LAM 
59 612 2 4 2 4 3 3 2 3 3 4 3 3 6 4 6 Ghana 
60 617 2 4 2 4 3 3 2 3 3 4 3 3 6 4 6 Ghana 
61 623 2 4 3 4 3 3 2 3 3 4 3 3 5 4 6 Ghana 
62 625 2 4 2 6 3 3 3 3 3 4 3 2 7 3 6 ND 
63 630 2 4 2 6 3 3 3 3 3 4 3 5 7 3 6 ND 
64 634 2 3 5 4 3 3 4 4 2 2 1 2 4 3 7 ND 
65 648 2 4 2 4 3 3 2 3 3 4 3 3 10 4 6 Ghana 
66 658 1 4 2 4 3 3 2 3 3 4 3 3 7 4 6 ND 
67 666 2 5 2 4 3 3 4 4 2 2 1 3 3 3 4 LAM 
68 668 2 4 2 4 3 3 2 3 3 4 3 2 6 4 5 ND 
69 682 3 5 5 2 3 3 3 4 4 2 3 1 3 1 5 ND 
70 686 2 5 2 3 4 3 2 4 2 2 3 2 4 2 5 ND 
71 691 2 6 1 4 3 3 1 3 3 4 2 3 4 2 8 ND 
72 697 2 4 2 4 3 3 2 3 3 4 3 6 7 4 6 Ghana 
73 706 2 4 3 4 3 3 2 3 3 4 3 5 5 4 6 Ghana 
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Anexo 2. Perfil MIRU-VNTR 15-Loci en aislados clínicos de Mycobacterium tuberculosis (Continuación) 
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74 760 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
75 765 2 5 7 4 3 3 3 4 2 1 2 2 2 3 7 LAM 
76 766 1 4 2 4 3 3 2 3 3 4 3 5 7 4 6  ND 
77 770 2 4 2 4 3 3 2 3 3 4 3 3 7 4 5  ND 
78 844 2 5 2 3 4 3 2 4 2 2 3 2 4 2 5  ND 
79 849 2 4 2 4 3 3 2 3 3 4 3 4 6 4 5  ND 
80 899 2 5 2 2 3 3 2 4 2 2 4 2 4 2 5 Cameroon 
81 932 2 5 0 4 3 2 3 4 2 1 3 2 2 3 6 LAM 
82 977 2 5 3 3 3 5 4 4 4 4 3 2 6 5 8 Beijing 
74 760 2 4 2 4 3 3 2 3 3 4 3 3 7 4 6 Ghana 
75 765 2 5 7 4 3 3 3 4 2 1 2 2 2 3 7 LAM 
76 766 1 4 2 4 3 3 2 3 3 4 3 5 7 4 6  ND 
77 770 2 4 2 4 3 3 2 3 3 4 3 3 7 4 5  ND 
78 844 2 5 2 3 4 3 2 4 2 2 3 2 4 2 5  ND 
79 849 2 4 2 4 3 3 2 3 3 4 3 4 6 4 5  ND 
80 899 2 5 2 2 3 3 2 4 2 2 4 2 4 2 5 Cameroon 
81 932 2 5 0 4 3 2 3 4 2 1 3 2 2 3 6 LAM 
82 977 2 5 3 3 3 5 4 4 4 4 3 2 6 5 8 Beijing 
ND, no determinado; MIRU-VNTR, Repeticiones en Tándem de Número Variable de Unidades Repetitivas Intercaladas Micobacterianas  
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Anexo  3. Ejemplo de una publicación en la revista seleccionada 
